<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05014607</url>
  </required_header>
  <id_info>
    <org_study_id>InHeVac01</org_study_id>
    <nct_id>NCT05014607</nct_id>
  </id_info>
  <brief_title>Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients</brief_title>
  <acronym>InHeVac01</acronym>
  <official_title>Personalized Multi-peptide Vaccination in Combination With the TLR1/2 Ligand XS15 in Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <brief_summary>
    <textblock>
      The aim of this project is to provide personalized multi-peptide vaccination in combination&#xD;
      with the TLR1/2 ligand XS15 to individual patients with advanced solid and hematological&#xD;
      malignancies without any approved treatment options.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ethics: Patient treatment will be conducted according to §13 Absatz 2b, AMG.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Personalized multi-peptide vaccine</intervention_name>
    <description>Peptide vaccine: Personalized multi-peptide vaccine cocktails consisting of 200-300µg each of 5-10 tumor-associated peptides selected individually based on the patient-individual HLA allotypes and HLA ligandome analysis of tumor cells Peptides are synthesized in the GMP-certified Wirkstoffpeptidlabor at the University of Tübingen and will be formulated at the GMP-Center of the University Hospital Tübingen.&#xD;
Peptides will be administered subcutaneously (s.c.) together with the TLR1/2 ligand XS15 emulsified in Montanide ISA 51 VG as adjuvant.&#xD;
Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned.&#xD;
Treatment schedule:&#xD;
Vaccination will take place every 6 weeks. A total of two to five vaccinations are planned, depended on the induction of peptide-specific T-cell responses.</description>
    <other_name>Adjuvants XS15 and Montanide ISA 51 VG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Documented diagnosis of advanced malignant disease&#xD;
&#xD;
          -  Advanced malignant disease without any available standard of care treatment option&#xD;
&#xD;
          -  Low tumor cell burden&#xD;
&#xD;
          -  Live expectancy &gt; 6 month&#xD;
&#xD;
          -  Ability to understand and voluntarily sign an informed consent form.&#xD;
&#xD;
          -  Ability to adhere to the study visit schedule and other protocol requirements&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating females.&#xD;
&#xD;
          -  Treatment regimens inducing sever T cell deficiencies&#xD;
&#xD;
          -  Treatment-related side effect &gt; CTC grade 2 (CTCAE V5.0&#xD;
&#xD;
          -  Participation in any clinical study or having taken any investigational therapy, which&#xD;
             would interfere with the studys primary and secondary end points within 2 weeks prior&#xD;
             to vaccination&#xD;
&#xD;
          -  Pre-existing auto-immune disease except for Hashimoto thyroiditis and mild (not&#xD;
             requiring immunosuppressive treatment) psoriasis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Helmut R Salih, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CCU Translational Immunology, University Hospital Tübingen, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juliane S Walz, MD</last_name>
    <phone>07071/2968746</phone>
    <email>kketi@med.uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Helmut R Salih, MD</last_name>
    <phone>07071/2968746</phone>
    <email>kketi@med.uni-tuebingen.de</email>
  </overall_contact_backup>
  <link>
    <url>https://www.medizin.uni-tuebingen.de/en-de/das-klinikum/einrichtungen/kliniken/medizinische-klinik/kke-translationale-immunologie</url>
    <description>Department CCU Translational Immunology</description>
  </link>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 23, 2021</study_first_submitted>
  <study_first_submitted_qc>August 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2021</study_first_posted>
  <last_update_submitted>September 6, 2021</last_update_submitted>
  <last_update_submitted_qc>September 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

